Phase 2 (Efficacy and Side Effects)

Phase 2 trials are designed to evaluate the efficacy and safety of investigational treatments before proceeding to large-scale confirmatory trials. While placebo-controlled designs are the gold standard for assessing efficacy, their use becomes ethically complex when an effective standard-of-care (SoC) treatment already exists. This tutorial explores how to ethically and scientifically manage placebo use in Phase 2 studies while preserving both patient safety and trial integrity.
Click to read the full article.

As investigational drugs advance through development, questions about continued access for participants after a Phase 2 study ends become increasingly important. Post-trial access (PTA) refers to the provision of a study drug or its alternatives to participants after the trial concludes—especially when they have shown benefit or have no other therapeutic options. In Phase 2, where therapies are still unapproved and risks are evolving, managing PTA ethically, operationally, and regulatory-wise requires thoughtful planning. This tutorial covers best practices for offering continued access to patients after a Phase 2 trial, particularly in life-threatening or chronic conditions.
Click to read the full article.

Early termination of a Phase 2 trial—whether due to futility, safety concerns, or overwhelming efficacy—is a critical decision that can impact patients, sponsors, regulators, and future development plans. While stopping a study early may be necessary, it must be based on pre-established criteria, ethical principles, and transparent communication. This tutorial outlines how to plan for and implement early termination in Phase 2 clinical trials with scientific, regulatory, and operational rigor.
Click to read the full article.

In certain therapeutic areas—especially rare diseases, oncology, and life-threatening conditions—randomized controlled trials may be impractical or ethically challenging in Phase 2. In such cases, researchers may use external or historical controls to assess treatment effect without a concurrent placebo or standard-of-care arm. This tutorial explores the strategic, statistical, and regulatory aspects of using external and historical data as control arms in Phase 2 clinical trials.
Click to read the full article.